Buy Glenmark Pharma, says Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Glenmark Pharma is an outperformer and I would be a willing buyer in it."

At 12:23 hrs Glenmark Pharma was quoting at Rs 972.60, up Rs 48.55, or 5.25 percent. It has touched a 52-week high of Rs 982.50.

The company's trailing 12-month (TTM) EPS was at Rs 35.71 per share. (Mar, 2015). The stock's price-to-earnings (P/E) ratio was 27.24. The latest book value of the company is Rs 103.05 per share. At current value, the price-to-book value of the company was 9.44. The dividend yield of the company was 0.21 percent.